Jonathan Taylor, MD
Urology · Greenville, NCNPI 1114134780
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 35.1% of the total.
Across 200 payments — averaging $32.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$2K
- Teleflex LLC$558
- Astellas Pharma US Inc$543
- Boston Scientific$524
- Johnson & Johnson$382
- Axonics, Inc.$362
- plus $2K from 19 others
Across 7 payments — averaging $2271.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$16K
What the payments were for
- Travel & lodging$1913%
- Food & beverage$5,87591%
- Education$3916%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 68 | $2,266 |
| Teleflex LLC | 6 | $558 |
| Astellas Pharma US Inc | 20 | $543 |
| Boston Scientific | 13 | $524 |
| Johnson & Johnson | 14 | $382 |
| Axonics, Inc. | 10 | $362 |
| Laborie Medical Technologies Corp. | 6 | $260 |
| Medtronic | 7 | $239 |
| Bayer | 7 | $228 |
| Endo Pharmaceuticals Inc. | 10 | $193 |
| AbbVie(2 entities) | 11 | $174 |
| Neotract Inc. | 3 | $122 |
| Pfizer | 7 | $117 |
| Merck | 1 | $108 |
| Intuitive Surgical | 1 | $90 |
| Urogen Pharma, Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Arrow International, Inc. | 3 | $47 |
| Tolmar, Inc. | 2 | $44 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 2 | $24 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $20 |
| Coloplast | 1 | $14 |
| Amgen | 1 | $13 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$275
- UroLift System$191
- XTANDI$125
- Nubeqa$125
- Axonics$111
- KEYTRUDA$108
- GreenLight XPS$107
How this compares
$6,458 in reported general payments places this provider in the 70th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 24 | $325,416 |
| MyrbetriqMirabegron | 162 | $92,145 |
| GemtesaVibegron | 39 | $28,328 |
| Tamsulosin Hcl | 572 | $7,651 |
| Solifenacin Succinate | 229 | $5,137 |
| Silodosin | 44 | $3,708 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 244 | $2,616 |
| Dutasteride | 82 | $2,095 |
| Estradiol | 36 | $2,080 |
| Methenamine Hippurate | 31 | $1,684 |
| Finasteride | 112 | $1,652 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 25 | $1,578 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,536 |
| Imipramine Hcl | 41 | $1,030 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 269 | $963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $543 | $417,561186 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $48 | $28,32839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 434 urology providers in North Carolina.
Other urology in Greenville
- Jonathan HamiltonGreenville$224K
- Matthew CollinsGreenville$41K
- Robert LippittSmithfield$11.4M
- Michael KennellyCharlotte$1.3M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Scott MacdiarmidGreensboro$774K
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.